Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin, 2018. 68(1): pp. 7–30.

Litwin MS, Tan HJ. The diagnosis and treatment of prostate Cancer: a review. JAMA. 2017;317(24):2532–42.

Article  PubMed  Google Scholar 

Kohaar I, Petrovics G, Srivastava S. A Rich array of prostate Cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci, 2019. 20(8).

Teo MY, Rathkopf DE, Kantoff P. Treat Adv Prostate Cancer Annu Rev Med. 2019;70:479–99.

CAS  Google Scholar 

von Amsberg G, Merseburger AS. [Treatment of metastatic, castration-resistant prostate cancer]. Urologe A. 2020;59(6):673–9.

Google Scholar 

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

Article  CAS  PubMed  Google Scholar 

Wu Z, et al. Emerging roles of aerobic glycolysis in breast cancer. Clin Transl Oncol. 2020;22(5):631–46.

Article  CAS  PubMed  Google Scholar 

Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013;123(9):3685–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang W, et al. Targeting Tumor Metabolism for Cancer Treatment: is pyruvate dehydrogenase kinases (PDKs) a viable anticancer target? Int J Biol Sci. 2015;11(12):1390–400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valvona CJ, et al. The regulation and function of Lactate dehydrogenase A: therapeutic potential in Brain Tumor. Brain Pathol. 2016;26(1):3–17.

Article  CAS  PubMed  Google Scholar 

Lin Y, Wang Y, Li PF. Mutual regulation of lactate dehydrogenase and redox robustness. Front Physiol. 2022;13:1038421.

Article  PubMed  PubMed Central  Google Scholar 

Sharma D, Singh M, Rani R. Role of LDH in tumor glycolysis: regulation of LDHA by small molecules for cancer therapeutics. Semin Cancer Biol. 2022;87:184–95.

Article  CAS  PubMed  Google Scholar 

Feng Y, et al. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7(12):6124–36.

Article  PubMed  PubMed Central  Google Scholar 

Xiang J, et al. Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by si–SAΤB1 in ovarian cancer. Oncol Rep. 2018;40(5):2788–97.

CAS  PubMed  Google Scholar 

Huo N, et al. STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis. Cell Death Dis. 2021;12(9):799.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xian ZY, et al. Inhibition of LDHA suppresses tumor progression in prostate cancer. Tumour Biol. 2015;36(10):8093–100.

Article  CAS  PubMed  Google Scholar 

Brisson L, et al. Lactate dehydrogenase B controls lysosome activity and autophagy in Cancer. Cancer Cell. 2016;30(3):418–31.

Article  CAS  PubMed  Google Scholar 

Leiblich A, et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene. 2006;25(20):2953–60.

Article  CAS  PubMed  Google Scholar 

Liu J, et al. Aberrant FGFR tyrosine kinase signaling enhances the Warburg Effect by Reprogramming LDH Isoform expression and activity in prostate Cancer. Cancer Res. 2018;78(16):4459–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joshi G, et al. Growth factors mediated cell signalling in prostate cancer progression: implications in discovery of anti-prostate cancer agents. Chem Biol Interact. 2015;240:120–33.

Article  CAS  PubMed  Google Scholar 

Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–29.

Article  CAS  PubMed  Google Scholar 

Winterhoff B, Konecny GE. Targeting fibroblast growth factor pathways in endometrial cancer. Curr Probl Cancer. 2017;41(1):37–47.

Article  PubMed  Google Scholar 

Ornitz DM, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271(25):15292–7.

Article  CAS  PubMed  Google Scholar 

Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang C, et al. Intrinsic FGFR2 and ectopic FGFR1 signaling in the prostate and prostate Cancer. Front Genet. 2019;10:12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sobhani N et al. Targeting aberrant FGFR signaling to overcome CDK4/6 inhibitor resistance in breast Cancer. Cells, 2021. 10(2).

Yang L, et al. FGF/FGFR signaling: from lung development to respiratory diseases. Cytokine Growth Factor Rev. 2021;62:94–104.

Article  CAS  PubMed  Google Scholar 

Klein RD, et al. Promatrilysin expression is induced by fibroblast growth factors in the prostatic carcinoma cell line LNCaP but not in normal primary prostate epithelial cells. Prostate. 1999;41(4):215–23.

Article  CAS  PubMed  Google Scholar 

Abraham JA, et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science. 1986;233(4763):545–8.

Article  CAS  PubMed  Google Scholar 

Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11(4):709–24.

Article  CAS  PubMed  Google Scholar 

Sun Y, et al. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling. Tumour Biol. 2017;39(7):1010428317712592.

Article  PubMed  Google Scholar 

Weaver AN, et al. Notch Signaling activation is Associated with Patient Mortality and increased FGF1-Mediated Invasion in squamous cell carcinoma of the oral cavity. Mol Cancer Res. 2016;14(9):883–91.

Article  CAS  PubMed  Google Scholar 

Henriksson ML, et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol. 2011;178(3):1387–94.

Article  PubMed  PubMed Central  Google Scholar 

Udayakumar TS, et al. Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. Int J Cancer. 2001;91(2):187–92.

Article  CAS  PubMed  Google Scholar 

Presta M, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16(2):159–78.

Article  CAS  PubMed  Google Scholar 

Dow JK, deVere RW, White. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 2000;55(6):800–6.

Article  CAS  PubMed  Google Scholar 

Poon RT, et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg. 2001;182(3):298–304.

Article  CAS  PubMed  Google Scholar 

Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999;5(5):1063–71.

CAS  PubMed  Google Scholar 

Cronauer MV, et al. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate. 1997;31(4):223–33.

Article  CAS  PubMed  Google Scholar 

Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654–67.

Article  CAS  PubMed  Google Scholar 

Lu W, Li X, Luo Y. FGF21 in obesity and cancer: new insights. Cancer Lett. 2021;499:5–13.

Article